Biotech Series A Investors & VC Firms

1596 firms in this list, with a median first check of $500K. 341 of them lead rounds. Generated from verified public data and updated continuously.

Fund	FoxScore	HQ	Invests	Stage	Check	CRM
H H Venture Partners EEBB2 people · Follows rounds	88🔒	Cincinnati	US	Seed–Late Stage	$250K – $5M	+ Add to CRM
NO Noetic SSWW2 people	88🔒	Toronto, Ontario	CA	Seed–Series A	—	+ Add to CRM
PR Propagator Ventures AFAEETAA7 people	88🔒	Oslo	NO	Pre-Seed–Series A	—	+ Add to CRM
IN iNetworks ALAJMDGM9 people	88🔒	Pittsburgh	US	Seed–Late Stage	—	+ Add to CRM
KI KIC Ventures KRAHVLAW9 people	88🔒	Fort Lauderdale	US	Seed–Late Stage	—	+ Add to CRM
MI Militia Hill Ventures JHJLBDS9 people	88🔒	Philadelphia	US	Seed–Series A	—	+ Add to CRM
PA Pathway Bioventures DJMMJSDH5 people	88🔒	Chicago	US	Pre-Seed–Series A	—	+ Add to CRM
SC Scientific Health Development AOPRSFMS5 people	88🔒	Dallas	US	Pre-Seed–Series A	$2M	+ Add to CRM
AC Access Biotechnology LRCB2 people · Leads rounds	88🔒	New York City	US	Seed–Late Stage	—	+ Add to CRM
ZÜ Zühlke Ventures PGSW2 people · Follows rounds	88🔒	Zurich	CH	Pre-Seed–Series A	$165K – $275K	+ Add to CRM
BR Bridge to Growth GGMBSSFW4 people	88🔒	Berlin	DE	Series A–Late Stage	$1.1M – $5.4M	+ Add to CRM
OP OphthaFund GMTMAMJT7 people · Leads rounds	88🔒	Charleston	US	Pre-Seed–Series A	—	+ Add to CRM
RT RTW Investments L.P. NYGMJKLC16 people	88🔒	New York	US	Seed–Series A	—	+ Add to CRM
TR Triatomic Capital JHPZSHWV6 people · Leads rounds	88🔒	Palo Alto	US	Seed–Series C	$100K – $1M	+ Add to CRM
RO Roche Venture Fund AHDESGCN6 people	88🔒	Basel	CH	Seed–Growth	$648K – $3.2M	+ Add to CRM
ST Start Capital Follows rounds	88🔒	—		Pre-Seed–Series A	—	+ Add to CRM
AZ AZ Venture Capital Inc. JGSRJPJN5 people · Follows rounds	88🔒	Phoenix	US	Pre-Seed–Series B	—	+ Add to CRM
CL Clal Biotechnology Industries AALNAFBG8 people	88🔒	Tel Aviv	IL	Seed–Late Stage	—	+ Add to CRM
DE DEFTA Partners GHEBKWMI8 people	88🔒	San Francisco	US	Seed–Series A	—	+ Add to CRM
HB HBS Alumni Angels EDJKTLYB5 people · Leads rounds	88🔒	Palo Alto	US	Pre-Seed–Series A	$750K – $2M	+ Add to CRM
JS JSD Capital, LLC JMJSAHGM8 people	88🔒	New York	US	Seed–Late Stage	$10M	+ Add to CRM
EL Elmehøj Ventures AR1 person · Follows rounds	88🔒	Copenhagen	DK	Pre-Seed–Series A	—	+ Add to CRM
KE Kern Capital, LLC JK1 person · Leads rounds	88🔒	Larkspur	US	Seed–Late Stage	$5M – $15M	+ Add to CRM
AV Avant Bio DKSLLUMW7 people · Leads rounds	88🔒	New York	US	Seed–Growth	—	+ Add to CRM

H Venture Partners

CincinnatiSeed–Late Stage$250K – $5M

EEBB2 people

Noetic

Toronto, OntarioSeed–Series A

SSWW2 people

Propagator Ventures

OsloPre-Seed–Series A

AFAEETAA7 people

iNetworks

PittsburghSeed–Late Stage

ALAJMDGM9 people

KIC Ventures

Fort LauderdaleSeed–Late Stage

KRAHVLAW9 people

Militia Hill Ventures

PhiladelphiaSeed–Series A

JHJLBDS9 people

Pathway Bioventures

ChicagoPre-Seed–Series A

DJMMJSDH5 people

Scientific Health Development

DallasPre-Seed–Series A$2M

AOPRSFMS5 people

Access Biotechnology

New York CitySeed–Late Stage

LRCB2 people

Zühlke Ventures

ZurichPre-Seed–Series A$165K – $275K

PGSW2 people

Bridge to Growth

BerlinSeries A–Late Stage$1.1M – $5.4M

GGMBSSFW4 people

OphthaFund

CharlestonPre-Seed–Series A

GMTMAMJT7 people

RTW Investments L.P.

New YorkSeed–Series A

NYGMJKLC16 people

Triatomic Capital

Palo AltoSeed–Series C$100K – $1M

JHPZSHWV6 people

Roche Venture Fund

BaselSeed–Growth$648K – $3.2M

AHDESGCN6 people

Start Capital

Pre-Seed–Series A

AZ Venture Capital Inc.

PhoenixPre-Seed–Series B

JGSRJPJN5 people

Clal Biotechnology Industries

Tel AvivSeed–Late Stage

AALNAFBG8 people

DEFTA Partners

San FranciscoSeed–Series A

GHEBKWMI8 people

HBS Alumni Angels

Palo AltoPre-Seed–Series A$750K – $2M

EDJKTLYB5 people

JSD Capital, LLC

New YorkSeed–Late Stage$10M

JMJSAHGM8 people

Elmehøj Ventures

CopenhagenPre-Seed–Series A

AR1 person

Kern Capital, LLC

LarkspurSeed–Late Stage$5M – $15M

JK1 person

Avant Bio

New YorkSeed–Growth

DKSLLUMW7 people

Data sourced from public filings and firms' own websites — see our methodology.